Shengya Xu, MD (they/them/theirs)

PEKING UNIVERSITY FIRST HOSPITAL
Beijing, China

Shengya Xu, MD, is a PhD Candidate in the Department of Endocrinology at Peking University First Hospital. Her research focuses on the immunometabolic mechanisms of Graves’ disease, with particular interest in B-cell differentiation, antibody production, and the regulatory role of hydrogen sulfide. She is currently investigating how hydrogen sulfide modulates B-cell function and immune imbalance in Graves’ disease.

Disclosure information not submitted.

Presentation(s):

• SUN-339 - Autoreactive Cd21Low B Cells Are Expanded in Graves' Disease and May Contribute to Autoantibody Production

  Sunday, June 14, 2026
  9:00 AM - 4:00 PM CT

• MON-349 - Hydrogen Sulfide Is Reduced in Graves' Disease and May Attenuate Autoantibody Secretion

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT

• ORF49-02 - Hydrogen Sulfide Is Reduced in Graves' Disease and May Attenuate Autoantibody Secretion

  Monday, June 15, 2026
  1:50 PM - 1:55 PM CT